TABLE 1.
Antibiotic susceptibility patterns of the A. baumannii isolates investigateda
| Antibiotic substance | Result for isolate(s): |
||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P1a | P1b, P2, P9, E1, E2, E5 | P3 | P4-P6, P8, P10 | P7 | P11, P16 | P12, P22, P25, P26 | P13 | E3 | E4 | P14 | P15 | P17, P18a | P18b | P19 | P20 | P21 | P23 | P24 | |
| Piperacillin | S | R | R | R | R | S | I | I | NT | NT | R | R | R | R | R | I | I | I | I |
| Piperacillin/tazobactam | S | R | R | R | R | S | S | S | S | S | S | S | S | R | S | S | S | S | S |
| Ceftazidime | R | R | R | R | R | S | S | S | I | I | I | S | S | R | S | S | S | I | I |
| Cefepime | NT | NT | R | R | R | S | S | S | NT | NT | I | NT | S | R | R | R | S | I | I |
| Imipenem | S | S | I | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S |
| Meropenem | S | S | I | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S |
| Gentamicin | S | R | R | R | R | S | S | S | S | S | S | S | S | S | S | S | S | S | S |
| Ciprofloxacin | S | R | R | R | R | S | S | R | I | S | S | S | S | I | S | S | S | R | S |
| Tigecycline | S | NT | I | I | R | S | S | NT | NT | NT | S | S | S | I | S | S | S | NT | S |
| Trimethoprim-sulfamethoxazole | S | R | R | R | R | S | S | S | S | S | S | S | S | S | S | S | R | S | I |
| Overall rated as | Non-MDR | MDR | MDR | MDR | MDR | Non-MDR | Non-MDR | MDR | Non-MDR | Non-MDR | Non-MDR | Non-MDR | Non-MDR | MDR | Non-MDR | Non-MDR | Non-MDR | MDR | Non-MDR |
a
Antibiotic susceptibility was determined using a Vitek II system (bioMérieux, Marcy-l'Étoile, France); testing was performed in accordance with EUCAST guidelines (versions 3.1 to 5.0). S, susceptible; I, intermediate; R, resistant; NT, not tested.